F
eline leukemia virus (FeLV) is a simple gammaretrovirus that naturally infects domestic cats and is capable of causing degenerative, proliferative, and malignant diseases of myeloid, erythroid, and lymphoid origin (1) . Three FeLV subgroups have been recognized and are distinguished by differences in the viral surface glycoprotein (SU) and in the cellular receptor used for virus entry (2) . The predominant subgroup, designated FeLV-A, represents the transmissible form of the virus spread cat-to-cat in nature and from which the other subgroups, designated FeLV-B and -C, arise de novo during the course of infection (3) (4) (5) . FeLV-A is weakly pathogenic in nature but is associated in unvaccinated animals with the induction of leukemia and lymphoma. Experimental infection with FeLV-A typically results in thymic lymphoma of Tcell origin after prolonged latency of one to three years (6) (7) (8) .
The isolate designated FeLV-945 was identified as predominant in a natural geographical and temporal cohort of domestic cats treated at a single veterinary clinic in Pasadena, CA, over a period of 6 years (9) (10) (11) . Although the cohort included cases of thymic lymphoma, multicentric lymphoma, mast cell leukemia, anemia, and myeloproliferative disease, FeLV-945 was associated exclusively with non-T-cell diseases. Host tropism, superinfection interference properties, and sequence analysis placed FeLV-945 in the FeLV-A subgroup (9, 12) . The largest sequence divergence between FeLV-945 and other FeLV-A members was identified in the SU protein and the viral transcriptional regulatory elements included in the long terminal repeat (LTR). The LTR of FeLV-945 contains a unique tandem 21-bp triplication that acts as a transcriptional enhancer and confers a replicative advantage to the virus in a cell type-specific manner (10, 11, 13) . The repeat junctions of the triplication create binding sites for the transcription factor, c-Myb, which upon binding recruits the transcriptional coactivator CBP to the viral promoter (14) . The role of the unique sequence elements of FeLV-945 in pathogenesis was investigated by experimental infection of separate litters of unrelated neonatal cats with either the FeLV-A prototype virus, FeLV-A/61E, or with recombinant virus in which the FeLV-945 LTR or the FeLV-945 envelope (env) gene and LTR were substituted for homologous sequences in FeLV-A/61E (6) . As predicted from previous studies (7, 8) , infection with FeLV-A/61E resulted in thymic lymphoma of T-cell origin after a long latency of 68 weeks. Infection with 61E/ 945L, the recombinant virus with the FelV-945 LTR, similarly induced T-cell lymphoma of the thymus but did so with a significantly shorter latency of 26 to 57 weeks. These results implicated the unique FeLV-945 LTR as a determinant of disease kinetics. Infection with 61E/945SL, the recombinant virus with both the FeLV-945 LTR and the FeLV-945 env gene, resulted in the more rapid disease progression associated with the FeLV-945 LTR but directed non-T-cell disease. Of four animals infected with 61E/ 945SL, three developed multicentric lymphoma of B-cell origin after a relatively short latency of 38 to 49 weeks. The results recapitulated observations from the natural cohort in that infection with a virus containing the unique elements of FeLV-945 was associated with non-T-cell disease. Further, the results implicated FeLV-945 SU as the determinant of the disease spectrum (6) .
As is typical of gammaretroviruses, FeLV SU contains a receptor-binding domain comprised of variable region A (VRA) and variable region B (VRB) and an adjacent proline-rich region (PRR) necessary for conformational changes that facilitate fusion of the viral envelope and cell surface (2, 3, 15) . FeLV-945 SU includes scattered amino acid differences compared to prototype FeLV-A/61E, although the differences are concentrated in the functional domains of the protein, VRA, VRB, and PRR (12) . Recent studies showed that both FeLV-945 viral particles and soluble FeLV-945 SU bind the FeLV-A receptor with significantly increased efficiency compared to FeLV-A/61E. A single amino acid change at position 186 in FeLV-945 SU was shown to be largely responsible for this effect, as this is a position outside the defined functional domains of SU and which replaced the isoleucine of FeLV-A/61E for a valine in FeLV-945. Computational modeling of the receptor-binding surface of the SU proteins predicted that the conservative change of valine for isoleucine at position 186 exerts influence over an adjacent glutamine at position 110. The more compact structure of valine 186 is predicted to allow reorientation of glutamine 110 out of the lower end of the putative binding cleft, thus widening the binding surface, which may then present an optimized binding conformation (16) . Taken together with previous studies on the pathogenesis of infection with 61E/945SL, the results implicate FeLV-945 SU as a determinant of disease spectrum and suggest that it may act in that role in the absence of other unique sequence elements of FeLV-945, including the LTR. The present study was designed to test that hypothesis.
MATERIALS AND METHODS
Preparation of virus stocks. An infectious molecular clone of FeLV-A/ 61E (17) was obtained from the NIAID AIDS Research and Reference Reagent Program. Recombinant infectious FeLV provirus in which the FeLV-945 LTR and env gene were substituted for homologous sequences in FeLV-A/61E was designated 61E/945SL and was constructed as previously described (12) . Recombinant infectious FeLV provirus in which the FeLV-945 SU gene was substituted for homologous sequences in FeLV-A/61E was designated 61E/945S and was generated by subcloning a 1,114-base-pair (bp) MscI/NcoI fragment of FeLV-945 corresponding to bp 100 to 1214 of the env gene into the corresponding region in p61E. To prepare infectious viral stocks, plasmid DNA containing the proviral genome of FeLV-A/61E, 61E/945SL, or 61E/945S was introduced into FEA feline embryonic fibroblasts (18) by transfection with Lipofectamine 2000 transfection reagent according to the manufacturer's instructions (Life Technologies, Grand Island, NY). Virus-containing supernatants were collected three to five days posttransfection and used to infect FEA cells in the presence of 8 g/ml hexadimethrine bromide (Sigma-Aldrich, St. Louis, MO). Four to seven days later, culture supernatants were harvested, passaged through a 0.22-M-pore-size filter, and concentrated using Vivaspin 20 centrifugal concentrators (Vivaproducts, Littleton, MA). The titer of each virus stock was determined by quantifying the 50% tissue culture infectious dose (TCID 50 ). For this purpose, FEA cells were seeded at a density of 5 ϫ 10 3 cells per well in 24-well culture dishes and challenged with 3-fold serial dilutions of each stock in quadruplicate wells in the presence of hexadimethrine bromide (Sigma-Aldrich) at 8 g/ml. After 48 h, the cells were washed twice with Hanks' balanced salt solution (Life Technologies) and were maintained for 22 days. At that time, supernatant from each well was assayed by antigen capture enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's directions (Zoetis, Pittsburgh, PA) for the presence of FeLV p27
Gag antigen. The TCID 50 was defined as the lowest dilution of the virus stock that resulted in infection in 50% of the wells.
In vivo challenge and longitudinal monitoring of infection and disease progression. FeLV-free, unvaccinated pregnant dams were obtained from Liberty Research, Inc. (Waverly, NY). Animals were housed according to the Guide for the Care and Use of Laboratory Animals in an AAALAC-I-accredited facility. All research using animals was reviewed and approved by Tulane University's IACUC. Within the first 24 h postpartum, separate and unrelated litters of neonatal kittens were inoculated intraperitoneally with 5 ϫ 10 5 TCID 50 of either FeLV-A/61E, 61E/945SL, or 61E/945S in a volume of 0.5 ml. Infected animals were observed by daily monitoring and weekly physical examinations for evidence of disease, including progressive weight loss, anorexia, diarrhea, dehydration, pallor, inactivity, or debilitation. Peripheral blood was collected from each animal every 2 weeks postinfection for the first 8 weeks and then monthly thereafter to test for FeLV viremia and for harvesting of DNA. Bone marrow samples were collected from each animal every 8 weeks postinfection for harvesting of DNA. Upon evidence of disease, complete necropsy was conducted and tissues were submitted for histopathological examination.
Immunohistochemical analysis of diseased tissues. Formalin-fixed, paraffin-embedded tissue sections (5 to 6 m thick) were examined by immunohistochemical staining using the following primary antibodies: (i) mouse monoclonal clone C11D8 directed against FeLV gp85/gp70 env (Custom Monoclonal antibodies International, West Sacramento, CA), (ii) rabbit polyclonal antibody directed against human and murine CD3 (Biocare Medical, Concord, CA), and (iii) rat monoclonal antibody directed against mouse CD45R/B220 (BD Biosciences, San Jose, CA). Reactivity to primary antibodies was detected using the MACH3 alkaline phosphatase polymer detection kit from Biocare Medical (Concord, CA) with the BCIP/NBT substrate system from Dako (Carpinteria, CA), after which sections were counterstained using YO-PRO nuclear stain (Life Technologies, Grand Island, NY). As controls, duplicate sections were processed in the absence of primary antibody.
Southern blot analysis of tumor tissues. High-molecular-weight genomic DNA was isolated from tumor tissues, and Southern blots were prepared and hybridized as previously described (19, 20) . For analysis of proviral integration patterns, tumor DNA was digested with KpnI and hybridized to a probe representing the LTR U3 region of exogenous FeLV (21) . Organization of the T-cell receptor beta (TCR␤) locus was examined by using the 86T5 probe, a 600-bp EcoRI fragment of murine TCR␤ cDNA (22) , on HincII-digested DNA. The pim-1 locus was analyzed by probing EcoRV-digested DNA with a probe representing feline pim-1 exon 5 (23) . The flvi-1 locus was analyzed by probing KpnI-digested DNA with a 1.0-kb PstI/EcoRI fragment, by probing HindIII-digested DNA with a 0.9-kb SmaI/KpnI fragment and a 1.0-kb BamHI/SacI fragment, and by probing EcoRI-digested DNA with a 0.8-kb SmaI/KpnI fragment (19) . The flvi-2 locus was analyzed by probing SstI-digested DNA with probe D (1.1-kb EcoRI fragment) (20) . The fit-1 locus was analyzed by probing SstI-digested DNA with the 600-bp NcoI fragment, probe C (23, 24) . The c-myc locus was analyzed by probing EcoRI-digested DNA with a BamHI/EcoRI fragment representing feline c-myc exon 3 (21) . The c-myb locus was analyzed by probing EcoRI-and KpnI-digested DNA with a 1.3-kb KpnI/XbaI fragment of v-myb (25) .
Isolation of FeLV integrations from tumor DNA and assessment of clonality. FeLV proviral integrations from thymic lymphomas of animals U2, U4, U5, U9, U10, and U12 and abdominal lymphoma from animal U12 were isolated using the GenomeWalker universal kit (Clontech Laboratories, Mountain View, CA) as per the manufacturer's instruction. Briefly, libraries were constructed by ligating GenomeWalker adaptors to tumor DNA that had been digested with DraI, EcoRV, PvuII, or StuI restriction endonucleases. Nested PCR amplification of the DraI library was performed using primary PCR primers AP1 (Clontech) and GW61ELTR(307-282) (5=-TAAATGAGGCGGAAGGTCGAACTCTG-3=) and using secondary PCR primers AP2 (Clontech) and 61ELTR(78-53) (5=-ACTTGAGTAATTTTCCATGCCTTGTG-3=). Nested PCR amplification of the EcoRV library was performed using primary PCR primers AP1 and GW61ELTR(156-185) (5=-CCAAGAACAGTTAAACC CCGGATATAGCTG-3=) and using secondary PCR primers AP2 and GWLTR(345-372) (5=-CGCTTTCTGCTATAAAACGAGCCATCAG-3=). The PvuII and StuI libraries were amplified by both primer sets listed above. PCR conditions were as follows: 1 cycle of 94°C for 15 s, 7 cycles of 94°C for 2 s followed by 70°C for 3 min, 32 cycles of 94°C for 25 s followed by 65°C for 3 min, and 1 cycle extension of 68°C for 10 min. Secondary PCR products were ligated into the pGEM-T Easy vector (Promega, Madison, WI) according to the manufacturer's instructions and sequenced by GENEWIZ, Inc. (South Plainfield, NJ) utilizing T7 and SP6 primer-binding sites in the vector. The resulting sequence from each integration was compared to the assembled Felis catus RefSeq genome and the nucleotide collection at NCBI using BLAST. To determine whether each FeLV integration thus isolated represented a clonal integration in tumor DNA, Southern blot analysis was performed to compare the affected locus in tumor DNA to that in uninvolved tissue of the same animal using radiolabeled probes corresponding to host DNA adjacent to each host-virus junction.
Detection of clonal integrations in longitudinally collected blood and bone marrow samples. DNA from 100-l samples of longitudinally collected blood and bone marrow was extracted using the DNeasy blood and tissue kit (Qiagen, Valencia, CA) as per the manufacturer's instruction. Bone marrow DNA was treated using 1.2 U of heparinase I (New England BioLabs, Ipswich, MA) per microgram of DNA prior to PCR. The presence of FeLV integrations that were identified as clonal in tumor DNA was examined in blood or bone marrow by nested PCR amplification of 0.25 g DNA using primer pairs directed against the viral LTR and host DNA sequences at the integration site. The FeLV LTR primers used for primary and secondary amplification in all cases were GW61ELTR(78-53) (see above) and 61ELTR(46-26) (5=-GGCACCACTGCAGTAGCTGGC-3=), respectively. Primers directed against host DNA were as follows, for primary and secondary PCR, respectively: 5=-GCATCTTCTACTACAGA CACTGGTCTG-3= and 5=-CCAACCACTGCCTCCCAGTC-3= for U2 thymic tumor, 5=-GACCTTTACCTGTTGTATGCAGAG-3= and 5=-GCC GTGGCTAATGGCACTGC-3= for U4 thymic tumor, 5=-CAAAGGTGTT CTAGTAGGAGCATAG-3= and 5=-GGGAGCGGAGTTCTGCCATG C-3= for U5 thymic tumor, 5=-GAGGTTTCAAGAGCATTATCGTGG-3= and 5=-GCACCAGTCCCAGAACTGCC-3= for U9 thymic tumor, 5=-GA ATACTCACGATAATAGCTGAGGAGC-3= and 5=-GCTGAGGAGCCC CAAGTCTC-3= for U10 thymic tumor, 5=-GTTTACTACACTGCGGTG CATTCAC-3= and 5=-GCACCTGGCCTGTGAGTGCAG-3= for U12 thymic tumor, 5=-GATCTACTTGCACCTACCTACTCTG-3= and 5=-CC AGAGAGGCTGGGTCTCTGC-3= for U12 abdominal tumor. PCR conditions were as follows: 1 cycle of 95°C for 2 min, 35 cycles of 95°C for 30 s followed by 50°C/60°C (primary/secondary PCR) for 30 s and 72°C for 60 s, and 1 cycle extension of 72°C for 5 min. After gel electrophoresis of the secondary PCR products, bands corresponding to the appropriate size were excised and submitted for sequencing (GENEWIZ, Inc., South Plainfield, NJ) using the appropriate internal primers. Secondary PCR products were also electrophoresed on 1.5% agarose gels and transferred to nitrocellulose for Southern blotting with integration site-specific probes. The lower limit of detection was assessed by amplification of a clonal integration from the thymic lymphoma of cat U5 using serial 10-fold dilutions of tumor DNA into 100 ng of DNA from the spleen of an uninfected cat.
PCR amplification and sequencing of the FeLV SU gene from tumor tissues. The FeLV env gene was amplified by PCR from diseased tissues of two animals infected with FeLV-A/61E and from three animals infected with 61E/945SL or 61E/945S. Amplification was conducted using primers H18 and H20 as previously described (6), except AccuPrime Pfx DNA polymerase was used according to the manufacturer's instructions (Life Technologies). PCR conditions were as follows: 1 cycle of 95°C for 5 min, 35 cycles of 95°C for 30 s followed by 56°C for 30 s and 68°C for 2 min 30 s, and 1 cycle extension of 72°C for 15 min. DNA was extracted after gel electrophoresis, digested with MscI, and cloned into SmaI-digested pBluescript II SKϩ (Agilent Technologies, La Jolla, CA). Eight to 10 clones were isolated from PCR amplifications from each tissue and were submitted for sequencing (GENEWIZ, Inc., South Plainfield, NJ) using primer 945env(973-955) (5=-CTTCGTAATAGGGTGGTCG-3=).
Nucleotide sequence accession numbers. Nucleotide sequences from FeLV integration sites identified as clonal in tumor DNA were submitted to GenBank with accession numbers JX967275 to JX967281.
RESULTS
FeLV-945 SU alters pathogenesis, although incompletely, in the absence of FeLV-945 LTR. To study the influence of FeLV-945 SU on pathogenesis in the presence or absence of the FeLV-945 LTR, a recombinant infectious FeLV provirus termed 61E/945S was constructed in which the SU gene of FeLV-945 was substituted for the homologous sequence in FeLV-A/61E. Pathogenesis directed by 61E/945S could then be compared to 61E/945SL, a recombinant generated previously (12) in which the FeLV-945 env and LTR were substituted for homologous sequences in FeLV-A/61E. For this purpose, a single litter of six neonatal kittens was inoculated intraperitoneally with 5 ϫ 10 5 TCID 50 of 61E/945S within the first 24 h after birth. Similarly, separate and unrelated litters containing four kittens each were inoculated with either 61E/ 945SL or the prototype FeLV-A/61E. At regular intervals thereafter, viremia was measured by antigen capture ELISA for the major capsid protein p27Gag in peripheral blood (Table 1) . Viremia was detected at a high level in all but one infected animal in the first blood draw collected at 2 weeks postinoculation and in the remaining animal at the second blood draw collected 2 weeks later. High levels of viremia persisted in all animals throughout infection. Since the kittens were housed together with the dam until weaning at 8 weeks of age, the possibility of horizontal transmission to the dam was also examined by ELISA. In no case was such transmission observed except in a single blood draw, at 4 weeks postinoculation, of the 61E/945S-infected litter. In that case, lowlevel viremia in the dam was transient and remained undetectable throughout the remainder of the study. Kaplan-Meier survival curves (Fig. 1 ) demonstrated more rapid disease induction in animals infected with 61E/945SL (29 to 46 weeks postinoculation; average of 37 weeks) compared to that in animals infected with 61E/945S (58 to 81 weeks postinoculation; average of 75 weeks), reflecting the previously observed influence of the FeLV-945 LTR on disease kinetics (6) . The litter infected with FeLV-A/61E developed disease unexpectedly rapidly. Excluding an animal euthanized early in the study (see below), the remaining animals succumbed to FeLV-induced lymphoma between 38 to 44 weeks postinoculation (average of 40 weeks). Compared to the 61E/ 945S-infected litter, log-rank analysis of the data demonstrated the more rapid disease induction in either 61E/945SL-or FeLV-A/61E-infected litters to be statistically significant (P ϭ 0.01).
Animals were subjected to regular physical examination over the course of infection and, upon evidence of disease, were subjected to necropsy and detailed analysis of pathology (Table 1) . Of the litter infected with prototype FeLV-A/61E, animal U11 was euthanized at 6 weeks postinoculation due to generalized lymphadenopathy. Two other animals, U9 and U10, demonstrated the typical pattern of disease progression after infection with FeLV-A/ 61E (6-8) with severe dyspnea symptomatic of a very large thymic lymphoma (7.5 by 9.5 cm and 5 by 11 cm, respectively) that filled the chest cavity. Mild to severe enlargement of some lymph nodes was also observed, and U10 demonstrated a large abdominal mass. Histological and immunohistochemical analysis of thymic masses in both animals demonstrated high-level FeLV expression in tumor cells and complete replacement of the normal architecture with a CD3 ϩ /CD45R Ϫ lymphoma, indicative of T-cell origin of the tumor (Fig. 2A) . As evidenced by Southern blotting of tumor DNA, the T-cell receptor ␤ (TCR␤) locus was rearranged in these animals, confirming the T-cell origin (Fig. 2B) . The remaining animal, U12, was euthanized due to weight loss and lethargy and presented with a smaller thymic lymphoma (1.5 by 3 cm), enlargement of spleen and liver, and a large ileal mass. In contrast to animals U9 and U10, the thymic lymphoma from animal U12 contained populations of CD3 ϩ and CD45R ϩ cells, as did the ileal mass. As measured by Southern blotting, the TCR␤ locus was observed in the germ line configuration (Fig. 2C and D) .
Animals infected with 61E/945SL, the recombinant virus in which both FeLV-945 env and LTR were substituted into FeLV-A/ 61E, demonstrated an entirely different disease outcome. These animals developed a tumor classified as large cleaved-cell lymphoma, which involved the liver and other organs but excluded the thymus (Table 1) . Typically, the hepatic architecture was obliterated by an infiltrate of spindle-shaped cells with irregular nuclei and high-level FeLV expression but without staining for CD3 or CD45R (Fig. 3) . Consistent with the apparent non-T-cell origin, the TCR␤ locus was observed in germ line configuration by Southern blotting of all cases (data not shown). Approximately 5% of tumor cells stained with the macrophage marker, CD163 (data not shown). Of six animals inoculated with 61E/945S, the recombinant virus in which only the FeLV-945 SU gene was substituted into FeLV-A/61E, one survived to the study endpoint. The remaining animals developed lymphomas that typically involved the liver, lung, spleen, thymus, lymph nodes, and bone marrow (Table 1) . Of note, these animals did not demonstrate the dyspnea typical of FeLV-A/61E-induced disease and were typically euthanized due to lethargy, vomiting, and weight loss that met the endpoint criteria for the study. The diseased thymus in these animals was noted at necropsy as normal in size (U6), mildly enlarged (U7), or moderately enlarged (e.g., 3 by 4.5 cm in U2; 2 by 5 cm in U4), with severe enlargement only in one case (U5; 4 by 11 cm). Immunohistochemical analysis demonstrated high-level FeLV expression in tumor cells and an unusual pattern of cell surface markers. The thymic lymphoma from cat U2 demonstrated positive staining for CD45R but was negative for the CD3 marker and was designated unclassified lymphoma. Thymic lymphomas from U4, U5, and U7 demonstrated dual staining for both CD3 and CD45R ( Fig. 4; Table 1 ). Considering the dual expression of antigens typically considered markers for B or T cells, i.e., CD45R or CD3, respectively, and considering the location of tumors in the thymus of infected animals, Southern blot analysis was performed to examine the configuration of the TCR␤ locus in tumor DNA. The analysis revealed clonal TCR␤ gene rearrangement, evidence of T-cell origin, in tumors of the thymus and other sites from a Neonatal cats were inoculated with prototype FeLV-A/61E or with recombinant virus in which the FeLV-945 env gene and LTR, or the FeLV-945 SU gene alone, were substituted for homologous sequences in FeLV-A/61E. The recombinant viruses were designated 61E/945SL and 61E/945S, respectively. b FeLV viremia was determined by ELISA for the major capsid protein p27Gag using peripheral blood samples collected every 2 weeks beginning 2 weeks postinoculation (p.i.). c Gross pathology of organs was scored at necropsy on a scale of 1 to 5, where 1 is normal in appearance and 5 is severely enlarged or has another specific abnormality. The organs indicated in Table 1 were scored as 3, 4, or 5, except for animal U7, where the affected organs were scored as 2. d NA, not applicable. Animal U11 was euthanized at 6 weeks postinfection due to illness upon clinical exam that met the endpoint criteria for the study. Animal U3 survived to study endpoint (2 years postinfection).
FIG 1 Kaplan-Meier survival curve of animals inoculated with FeLV-A/61E
(61E) or infectious recombinant viruses 61E/945S and 61E/945SL. Animals infected with 61E/945S exhibit significantly longer survival than cats infected with FeLV-A/61E or 61E/945SL (P ϭ 0.01). The FeLV-A/61E-infected animal U11 was excluded from the analysis due to early euthanasia unrelated to tumor formation.
animals U2, U4, U5, and U7, despite the expression of CD45R (Fig. 5) . Tumor tissues from U6 stained with neither CD45R nor CD3. The tissues demonstrated a distinctive infiltrate of spindleto stellate-shaped cells and cells with irregular nuclei and cleaved appearance, leading to a morphological classification of large cleaved-cell lymphoma ( Fig. 4 ; Table 1 ). Southern blot analysis of the U6 thymic lymphoma revealed subclonal TCR␤ gene rearrangement (data not shown).
Analysis of FeLV proviral integration patterns demonstrates further distinction among the disease outcomes.
Southern blot analysis of tumor DNA was next used to examine the pattern of clonal FeLV proviral integrations in each tumor. In this analysis, digestion of tumor DNA with KpnI and hybridization with a probe for the U3 region of the exogenous FeLV LTR demonstrates two hybridizing fragments from each clonally integrated provirus: (i) an internal proviral fragment of 3.4 kb that is the same size for all integrants and (ii) a host-virus junction fragment unique in size for each integrant (Fig. 6 ). When performed on lymphomas induced by FeLV-A/61E or 61E/945S, the analysis demonstrated numerous clonally integrated proviruses in tumor-bearing tissues. In most cases, the analysis further demonstrated an identical pattern of clonal integrations among tumor-bearing tissues of the same animal, indicating the presence of a single, monoclonal tumor. The tumor from animal U12 was unusual, however, in that distinct clonal integration patterns were evident in the liver, kidney, thymus, and ileal mass. These differences indicate that multiple tumors may have arisen simultaneously in U12 and/or that cells within the original tumor evolved by selection or other processes as they spread through the animal. In contrast, clonally integrated proviruses were not readily detectable in diseased tissues from 61E/945SL-infected animals. Thus, it is not clear whether the tumors in 61E/945SL-infected animals represent clonal expansion of an originally transformed cell (Fig. 6) . The clonality of proviral integration in FeLV-induced lymphomas is typically associated with the interruption of one or more oncogene loci in tumor DNA. Such loci have been identified as common integration sites (CIS) in FeLV-induced tumors and include flvi-1, flvi-2 (bmi-1), fit-1, c-myc, and pim-1 (26) . Tumor DNA samples from all infected cats were screened by Southern blotting for the involvement of these CIS. Clonal integrations in c-myc were detected in tumors from four animals, including FeLV-A/61E-infected U10 and 61E/945S-infected U4, U5, and U7. Proviral interruption of known c-myc collaborators (23, 24, 27) was also identified in 61E/ 945S-infected cats, specifically at bmi-1 and c-myb in U4 and at fit-1 in U7. No involvement of any locus examined was identified in the tumor tissues from 61E/945SL-infected cats (data not shown).
Inasmuch as the pattern of clonal proviral integration in each tumor is characteristic of the originally transformed cell, the identification of specific clonal integrations affords a molecular tag by which the presence of tumor cells can be identified in samples collected longitudinally throughout infection, well before the tumor mass is evident. Having collected blood and bone marrow samples longitudinally in the present study, we set out to isolate clonal host-virus junctions from each tumor so as to utilize them as molecular tags for this purpose. Thus, proviral integrations were cloned as host-virus junction fragments from the thymic lymphomas of animals U2, U4, U5, U9, U10, and U12 and from the ileal tumor of animal U12 using the GenomeWalker kit (Clontech Laboratories). To determine which of the isolated host-virus junction fragments were clonal integrations in tumor DNA, a radiolabeled probe representing host sequences from each fragment was used as a probe in Southern blot analysis of tumor DNA. By this approach, a single clonal proviral integration was identified from the tumor tissue of each animal. Primers were then designed to cross the host-virus junction of each clonal integration event and used in PCR amplification of DNA from longitudinally collected blood and bone marrow samples. Amplification products were detected visually after gel electrophoresis or after hybridization to a radiolabeled probe representing the integration site and were verified by sequence analysis. Detection of an amplification product in this analysis is considered evidence for the presence of tumor cells in the tissue examined. The results of the analysis are summarized in Table 2 . In FeLV-A/61E-infected animals that developed thymic lymphoma of T-cell origin (U9 and U10), tumor cells could not be detected in bone marrow collected at any time after infection and were demonstrated in the blood of one animal only near the time of necropsy. Neither of two distinct tumors that arose in U12 were detectable in bone marrow samples collected at any time, but cells from the thymic tumor were evident in blood at 11 weeks prior to necropsy. In contrast, each of the clonal integrations identified from 61E/945S-induced tumors was readily de- tected in bone marrow and blood during the disease process. Tumor cells in animal U2 were evident in bone marrow 14 weeks prior to necropsy and in blood 10 weeks prior to necropsy. Tumor cells in animal U4 were detected in bone marrow and blood 2 and 5 weeks prior to necropsy, respectively. Tumor cells in animal U5 were detected 4 weeks prior to necropsy in bone marrow but were detected 23 weeks prior to necropsy in blood. As a control, DNA from the U5 thymic tumor was subjected to 10-fold serial dilution into 100 ng of DNA from an uninvolved tissue and amplified similarly. The specific amplification product was detectable under these conditions after a 1:100,000 dilution.
Stability of the FeLV SU gene over the course of infection. To verify the identity and stability of the FeLV SU gene over the course of disease in each infected litter, an 809-bp segment of the SU gene inclusive of the functional domains VRA, VRB, and PRR was amplified by PCR and sequenced from representative animals infected with each virus. Specifically, the SU gene sequence from bp 109 to 918 was determined from eight to 10 clones from PCR amplifications of each tumor DNA sample. As summarized in Table 3 , the results demonstrated scattered point mutations within and between the functional domains in all samples examined. Point mutations were not clustered and did not differ significantly between litters. Deletions in the VRA sequence of 18 bp or 6 bp were observed in animals infected with FeLV-A/61E or 61E/ 945SL, respectively. Insertions of variable length from 12 bp to 63 bp were observed in multiple clones from all 61E/945S-infected cats examined. Among animals infected with FeLV-A/61E or 61E/ 945SL, by comparison, only a single clone from one 61E/945SL-infected animal demonstrated insertion, that being within VRA. Amino acid sequence alignments of the insertions within VRA demonstrated some commonality in sequence and position (Fig.  7 ) but did not demonstrate sequence alignment with known endogenous FeLV elements as measured by BLASTP analysis (National Library of Medicine). An insertion of 9 bp in PRR was identified in a single clone from one FeLV-A/61E-infected animal (Table 3) . Of particular interest was the stability of SU residue 186, demonstrated in recent work to be largely responsible for the distinctive receptor-binding properties of FeLV-945 SU (16) . No mutation of the sequence at this residue was detected.
DISCUSSION
Natural FeLV-A isolates, including prototype FeLV-A/61E examined here, typically induce thymic lymphoma of T-cell origin after a prolonged latency of 2 years or more (7, 8) . In contrast, the natural FeLV-A isolate designated FeLV-945 was associated exclusively with non-T-cell disease (9) (10) (11) . Previous studies performed to identify the genetic elements responsible for its disease spectrum implicated the unique FeLV-945 LTR as a determinant of the rate of disease development and the FeLV-945 SU gene as a determinant of non-T-cell disease (6) . The study, while it implicated FeLV-945 SU as the determinant of disease spectrum, did not provide evidence as to the intrinsic influence of FeLV-945 SU, i.e., without the cooperating influence of the unique FeLV-945 LTR. Thus, the present study was designed to determine to what extent FeLV-945 SU acts as a determinant of pathogenesis in the natural host.
Results of experimental infection ( Fig. 1 ; Table 1 ) were generally consistent with previous studies in that the 61E/945SL recombinant virus, containing the FeLV-945 LTR and env gene, drove disease induction significantly more rapidly than did the 61E/945S virus, bearing the FeLV-945 SU alone. It was striking that the FeLV-A/61E-infected litter developed disease significantly more rapidly than has been reported previously (6) (7) (8) . Considering that the natural host is an outbred animal, it is possible that the genetics of the litter contributed an influence here that is not measurable in our assays. It seems unlikely that genetic variation in the virus inoculum was responsible for the increased rate of disease induction since most of the proviral SU genes cloned from two FeLV-A/61E-induced tumors demonstrated 99% to 100% identity to the published viral sequence. Point mutations or deletion were detected in occasional clones but were not identified in com- mon among clones from the two tumors (Table 3 ; some data not shown). As in previous studies (6-8), prototype FeLV-A/61E induced a thymic lymphoma of T-cell origin in infected animals ( Fig. 2A and B) . Animal U12, however, developed an unusual lymphoma that involved multiple organs, including the thymus, and stained with markers for both T-and B-cell lineage ( Fig. 2C  and D ). This observation is particularly noteworthy in the context of results from the litter infected with 61E/945S that developed a similar disease (Table 1) . While this disease outcome has not been reported previously in FeLV-A/61E-infected animals, the finding indicates the broad spectrum of disease outcomes that are possible when infected with this natural virus. Based on patterns of clonal proviral integration in tumor DNA (Fig. 6 ), multiple tumors appear to have arisen independently in animal U12 that demonstrate the dual staining for markers of both T-and B-cell lineage (data not shown). As in the infected litter from the previous study, virus 61E/945SL bearing both the LTR and env gene of FeLV-945 again induced non-T-cell disease, in this case a large cleaved-cell lymphoma that involved multiple organs but excluded the thymus. The lymphoma is of unknown cellular origin but did not stain with markers of T-or B-cell lineage (Fig. 3) . Of note is that the natural multicentric lymphomas from which FeLV-945 was originally isolated were similarly described as being of non-T-cell non-B-cell origin (9, 19) . The 61E/945S recombinant virus, bearing only the SU gene of FeLV-945, induced a disease outcome in the infected litter that was distinct from both FeLV-A/61E and 61E/ 945SL. The distinction was evident first in clinical presentation and at necropsy. While FeLV-A/61E animals U9 and U10 developed the severe dyspnea readily recognizable as a clinical symptom of large thymic lymphoma, 61E/945S-infected animals typically exhibited smaller tumors of the thymus, among other affected organs, and did not evidence dyspnea but met the clinical endpoint criteria of significant weight loss and lethargy. Histologic and immunohistochemical analysis revealed a CD45R ϩ lymphoma of unclassified origin in one case (U2), a dual-staining CD3 ϩ /CD45R ϩ lymphoma in three cases (U4, U5, U7), or a large cleaved-cell lymphoma that did not stain with either marker (U6) (Fig. 4) . While CD45R is typically considered a marker of B-cell origin, it is also expressed in the cytoplasm of normal thymocytes and on the surface of a subset of dendritic cells and certain abnormal and activated T cells (28) (29) (30) (31) (32) (33) (34) (35) . Thus, CD45R expression in this case may reflect a T-cell origin of the tumors. Indeed, evidence of clonal TCR␤ gene rearrangement in the lymphomas that expressed CD45R supports this interpretation (Fig. 5) .
Analysis of clonal proviral integrations at common insertion sites in tumors demonstrated frequent interruption of the c-myc locus or its known collaborators flvi-2 (bmi-1), fit-1, and c-myb, particularly in animals infected with 61E/945S. Tumors in three of five 61E/945S-infected animals demonstrated clonal proviral integration at c-myc, two of which also demonstrated clonal insertion at known c-myc collaborators, bmi-1, c-myb, and fit-1 (data b Sequence comparisons were analyzed in segments between and within the functional domains VRA, VRB, and PRR. Indicated is the number of base pairs in each segment. % identity, percent nucleotide sequence identity to the parental virus used to inoculate each animal, excluding deletions and insertions. The percent identity indicated represents the average of all clones examined from that tissue. Deletions of 18 bp and 6 bp were detected in proviruses from U10 and W4, respectively. An insertion of 9 bp was detected in the PRR region of proviruses in U10. Insertions in VRA in W2, U4, U6, and U7 varied in size from 12 to 63 bp, the translations of which are shown in Fig. 7 . Indicated is the number of individual clones in which deletion or insertion was identified relative to the total number of clones examined. Table 2 ). While the cell type of origin of these tumors is not known, the results suggest that tumor cells in 61E/945S-infected animals may originate in bone marrow, while FeLV-A/61E-induced thymic lymphomas arise in situ. Alternately, the early evidence of tumor cells in blood and bone marrow of 61E/945S-infected cats may reflect a more readily detected metastasis. Sequence analysis of the predominant proviral SU genes present in tumors demonstrated a generally high level of stability throughout the functional domains of SU and intervening sequences (Table 3) . Indeed, point mutations were no more likely to occur within the designated variable regions VRA and VRB than between them. The SU genes cloned from 61E/945S-infected animals uniformly contained insertions in VRA ranging from 12 bp to 63 bp. These appear to be evidence of early recombination, but upon translation, the inserted amino acid sequences did not align with known endogenous FeLV elements. While the source of the insertions remains unknown, their presence may reflect virus replication in a tissue where the environment is favorable for recombination. Alternatively, the frequency may reflect the longer latency to disease induction in 61E/945S-infected cats, thus affording more opportunity for recombination. Recently, the FeLV-945 SU was found to bind to the cellular receptor with significantly increased efficiency compared to that of the SU of FeLV-A/61E (16) . Increased binding efficiency could contribute to pathogenesis in at least two ways that are not mutually exclusive, i.e., by conferring increased spreading efficiency in the infected host and/or by conferring entry into an otherwise inaccessible cell type with low-level receptor expression. The present results do not support the first possibility in that high-level viremia was rapidly detected, typically within 2 weeks of inoculation, and was sustained in all animals regardless of the inoculum ( Table 1 ). The second possibility seems more likely, in that the distinctive phenotypes of tumors induced by virus that contains FeLV-945 SU suggest different cell types of origin.
In summary, several observations in the present study indicate that FeLV-945 SU alone, in the absence of the FeLV-945 LTR, acts to alter pathogenesis mediated by the parent virus, FeLV-A/61E. The tumors induced by 61E/945S were associated with distinctive clinical presentation marked by weight loss and lethargy over a prolonged period in the absence of dyspnea, the hallmark clinical sign of experimental FeLV-A infection. The tumors were of unusual immunohistochemical staining pattern, demonstrating expression of CD45R, of both CD3 and CD45R, or of neither marker. Clonal rearrangement of the TCR␤ locus indicated that the CD45R-expressing tumors are of T-cell origin (Fig. 5) . Thus, CD45R expression in these cases may not reflect B-cell origin as it is typically interpreted but appears to reflect tumor origin in normal thymocytes or certain abnormal and activated T cells in which CD45R is also expressed (28) (29) (30) (31) (32) (33) (34) (35) . The tumors were evident in bone marrow and blood at earlier times during the disease process, an observation that may reflect either the tissue of origin or the pattern of metastasis. Finally, the predominant SU genes from proviruses integrated in tumor DNA carried distinctive markers of genetic recombination. While the substitution of FeLV-945 SU into FeLV-A/61E alters virus-mediated pathogenesis, it does so incompletely. Evidence here (Fig. 3 ) and elsewhere (6) demonstrates that FeLV-945 SU and LTR are required together to recapitulate the distinctive non-T-cell disease outcome seen in the natural cohort. The observation is consistent with the precise conservation of unique repeat elements in the LTR and sequence motifs in the SU gene characteristic of FeLV-945 that occur together in nature.
